AP601

AP601 is a bispecific antibody drug candidate developed by AP Biosciences. It is currently in preclinical development and is being investigated for the treatment of neoplasms (cancers). The specific molecular targets, mechanism of action, and further details about its structure or binding epitopes have not been publicly disclosed. As a bispecific antibody, it is designed to simultaneously bind two different antigens or epitopes, which may enhance anti-tumor activity through mechanisms such as redirecting immune cells to tumor cells or dual pathway inhibition[1][3]. The developer, AP Biosciences, specializes in bispecific antibody platforms for oncology applications[4].

Brand names

Mircera

Other names

CERAContinuous erythropoietin receptor activator